Development of an implantable device to monitor lactate levels in blood: Monitoring the Performance of Australian athletes using Biosensor Technology. Sport is a critical area for social and economic investments. Novel medical monitoring systems using implantable biosensors will ensure optimal training programs for Australian athletes and maintain international competitiveness. Here we are developing a biosensor for real-time monitoring of lactate levels in athletes using frontier porous semicon ....Development of an implantable device to monitor lactate levels in blood: Monitoring the Performance of Australian athletes using Biosensor Technology. Sport is a critical area for social and economic investments. Novel medical monitoring systems using implantable biosensors will ensure optimal training programs for Australian athletes and maintain international competitiveness. Here we are developing a biosensor for real-time monitoring of lactate levels in athletes using frontier porous semiconductor technology and smart telemetry protocols to transfer the readings to a remote base unit. These highly innovative devices and the materials that they are made from have enormous commercial potential in biomedical engineering. There is a strong potential for Australia to have an important stake in this area by combining expertise in engineering, chemistry and nanostructured materials.Read moreRead less
Improved methods for quantitation of acute phase proteins in biological samples. Using monoclonal antibodies and fluorescence polarisation, we aim to develop improved quantitative analytical methods that are superior to the current clinical assays. The initial targets will be C-reactive protein (CRP) and serum amyloid precursor protein (SAP), but the technology should be readily adaptable to other serum proteins. Better assays for CRP and SAP will greatly facilitate improved clinical management ....Improved methods for quantitation of acute phase proteins in biological samples. Using monoclonal antibodies and fluorescence polarisation, we aim to develop improved quantitative analytical methods that are superior to the current clinical assays. The initial targets will be C-reactive protein (CRP) and serum amyloid precursor protein (SAP), but the technology should be readily adaptable to other serum proteins. Better assays for CRP and SAP will greatly facilitate improved clinical management of those at risk of heart attack, the single biggest contributor to healthcare costs in Australia. We further aim to adapt this technology to enable "point-of-care" assays that would help medical practitioners, especially in rural areas, to make informed diagnoses immediately.Read moreRead less